TY  - JOUR
A1  - Rothe, Achim
A1  - Claßen, Annika
A1  - Carney, Jonathan
A1  - Hallek, Michael
A1  - Mellinghoff, Sibylle Christiane
A1  - Scheid, Christoph
A1  - Holtick, Udo
A1  - Bergwelt‐Baildon, Michael von
T1  - Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis
T2  - European journal of haematology
N2  - Objective: Fluconazle or posaconazole is a standard of care in antifungal prophylaxis for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). However, many patients need to interrupt standard prophylaxis due to intolerability, drug‐drug interactions, or toxicity. Micafungin has come to prominence for these patients. However, the optimal biological dose of micafungin stays unclear.
Methods: We retrospectively evaluated the efficacy of micafungin as antifungal prophylaxis in HSCT patients. Micafungin was applied as bridging in patients who were not eligible to receive oral posaconazole. Micafungin was either given at a dose of 100 mg or 50 mg SID.
Results: A total of 173 patients received micafungin prophylaxis, 62 in the 100 mg and 111 in the 50 mg dose group. The incidence of probable or proven breakthrough IFDs during the observation period was one in the 100 mg and one in the 50 mg group. Fungal‐free survival after 100 days was 98% and 99% (P = .842), and overall survival after 365 days was 60% and 63% (P = .8) respectively. In both groups, micafungin was well tolerated with no grade 3 or 4 toxicities.
Conclusion: In this retrospective analysis, which was not powered to detect non‐inferiority, micafungin is effective and complements posaconazole as fungal prophylaxis in HSCT.
KW  - immunology and infectious diseases
KW  - transplantation
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/56304
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-563044
SN  - 1600-0609
VL  - 104.2020
IS  - 4
SP  - 291
EP  - 298
PB  - Wiley-Blackwell
CY  - Oxford
ER  -